MGMT and glioblastoma: All GBM cultures investigated in this study exhibit different extends of MGMT promoter methylation (PCa: 91.8%; PCb: 84.2%; GSCa: 41.8%; GSCb: 72.8%) and are therefore in principle able to respond to a TMZ treatment.